Form 4: Theravance Biopharma CFO Reports Share Disposal to Cover Tax Obligations
SEC Form 4 Filing
Aziz Sawaf, SVP & CFO of Theravance Biopharma, disposed of 8,635 ordinary shares to satisfy tax obligations related to vesting restricted stock units.
Summary
- On May 20, 2024, Aziz Sawaf, the SVP & CFO of Theravance Biopharma, disposed of 8,635 ordinary shares.
- The shares were disposed of at a price of $9.1.
- This transaction was to cover tax obligations arising from the vesting of previously granted restricted stock units.
- Following the transaction, Sawaf beneficially owns 330,001 ordinary shares.
Sentiment
Score: 7
Explanation: The sentiment is neutral as it reflects a routine transaction for tax purposes. It doesn't indicate any fundamental change in the company's prospects or insider confidence.
Industry Context
Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. This filing indicates a standard transaction to cover tax obligations, which is a common practice.
Stakeholder Impact
- The transaction has a minimal impact on stakeholders as it is a routine disposal of shares to cover tax obligations.
Key Dates
| Date | Description |
|---|---|
| 05/20/2024 | Date of share disposal transaction |
| 05/22/2024 | Date of signature by Attorney-in-Fact |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.